Deuruxolitinib Shows Promise in Treating Alopecia Areata
核心洞察
Deuruxolitinib, an oral JAK1 (搜索) and JAK2 (搜索) inhibitor, has demonstrated significant efficacy in stimulating hair regrowth in adults with moderate to severe alopecia areata (搜索).
The THRIVE-AA1 phase 3 trial showed that deuruxolitinib resulted in significantly higher proportions of patients achieving a SALT score ≤ 20 compared to placebo.
Patient-reported outcomes indicated higher satisfaction with hair regrowth in patients treated with deuruxolitinib compared to those receiving a placebo.
Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, has shown promising results in stimulating hair regrowth among adult patients with alopecia areata (搜索). The recent FDA approval of deuruxolitinib marks a significant advancement in the treatment of this condition, where effective treatments have been limited.
The THRIVE-AA1 trial (NCT04518995), a randomized, double-blinded, placebo-controlled study, evaluated the efficacy and safety of deuruxolitinib across 72 treatment sites in the US, Canada, and Europe. The study enrolled 706 patients who were randomized to receive deuruxolitinib 8 mg twice daily (n = 351), deuruxolitinib 12 mg twice daily (n = 215), or placebo (n = 140).
Efficacy Outcomes
Both doses of deuruxolitinib resulted in significantly higher proportions of patients achieving a Severity of Alopecia Tool (SALT) score less than or equal to 20 after 24 weeks compared to placebo. Specifically, 29.6% of patients in the 8 mg group and 41.5% in the 12 mg group achieved this outcome, compared to only 0.8% in the placebo group. Key secondary outcomes also showed significant improvements with both deuruxolitinib doses compared to placebo. At week 24, patient-reported satisfaction with hair regrowth was 42.1% in the 8-mg cohort and 53.0% in the 12-mg cohort, compared to 4.7% for placebo.
Treatment with deuruxolitinib also resulted in significantly higher SALT scores at weeks 8, 12, 16, and 20 compared with placebo. Furthermore, at 24 weeks, a greater proportion of patients treated with 8-mg (20.8%) or 12-mg (34.5%) twice-daily deuruxolitinib achieved a SALT score of 10 or higher compared with the placebo group.
Safety Profile
Most treatment-emergent adverse events (TEAEs) reported were of mild to moderate severity, consistent with the known profile of oral JAK inhibitors. Discontinuations due to TEAEs were more frequent in the 8-mg and 12-mg deuruxolitinib groups at 2.6% and 2.8%, respectively, compared with 1.4% in the placebo group.
Expert Commentary
According to the study authors, "Treatment with deuruxolitinib resulted in significant scalp hair regrowth as early as 8 weeks, which continued throughout the 24 week study period, with patient satisfaction reflecting the hair regrowth observed."
Considerations
The study was limited by the short duration of the double-blind period and restrictions due to the COVID-19 pandemic. Future studies are necessary to assess long-term safety and efficacy, as well as the durability of hair regrowth and the potential for alopecia areata (搜索) recurrence after treatment discontinuation.